Autoantibodies against tumor-related antigens: Incidence and biologic significance

Human Immunology

Volumn 71, Issue 7, 2010, Pages 643-651

  Kobold, Sebastian ^a   Lütkens, Tim ^a   Cao, Yanran ^a   Bokemeyer, Carsten ^a   Atanackovic, Djordje ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Autoantibodies; Human seronome; Tumor antigens; Tumor immunology

Indexed keywords

AUTOANTIBODY; CANCER TESTIS ANTIGEN; CELL ANTIGEN; DECOY ANTIGEN; GANGLIOSIDE LIKE ANTIGEN; NUCLEIC ACID SPECIFIC ANTIGEN; STEM CELL ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; FRAMESHIFT MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TUMOR IMMUNOLOGY;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIBODIES; HUMANS; NEOPLASMS;

EID: 77953914685     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.03.015     Document Type: Review

References (126)

1. Silberstein A.M. History of immunology 1989, Academic, San Diego.
2. Ehrlich P. About the current state of carcinoma research. Ned Tijdscher Geneeskd 1909, 5:18.
3. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
4. Burnet F.M. The concept of immunological surveillance. Prog Experiment Tumor Res Fortschr Exp Tumorforsch 1970, 13:1-27.
5. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity. Cellular and humoral aspects of the hypersensitive states 1959, 529-532. Hoeber-Harper, New York. H.S. Lawrence (Ed.).
6. Rygaard J., Povlsen C.O. Is immunological surveillance not a cell-mediated immune function?. Transplantation 1974, 17:135-136.
7. Street S.E., Trapani J.A., MacGregor D., Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002, 196:129-134.
8. Bui J.D., Schreiber R.D. Cancer immunosurveillance, immunoediting and inflammation: Independent or interdependent processes?. Curr Opin Immunol 2007, 19:203-208.
9. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
10. Black M.M., Kerpe S., Speer F.D. Lymph node structure in patients with cancer of the breast. Am J Pathol 1953, 29:505-521.
11. Canevari S., Pupa S.M., Menard S. Revised anti-cancer serological response: Biological significance and clinical implications. Ann Oncol 1975-1995, 7:227-232. Marine.
12. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994, 1:447-456.
13. Di Genova G., Roddick J., McNicholl F., Stevenson F.K. Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood 2006, 107:2806-2813.
14. Bei R., Masuelli L., Palumbo C., Modesti M., Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett 2009, 281:8-23.
15. Van den Eynde B.J., van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693.
16. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
17. Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007, 360:319-326.
18. Preuss K.D., Zwick C., Bormann C., Neumann F., Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002, 188:43-50.
19. Behrends U., Schneider I., Rossler S., Frauenknecht H., Golbeck A., Lechner B., et al. Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Int J Cancer 2003, 106:244-251.
20. Comtesse N., Zippel A., Walle S., Monz D., Backes C., Fischer U., et al. Complex humoral immune response against a benign tumor: Frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A 2005, 102:9601-9606.
21. Cui X.B., Xie K., Liang G.C., Deng H.X., Wei Y.Q., Tian L. [Screening and identification of human nasopharyngeal carcinoma-associated antigens]. Sichuan da Xue Xue bao Yi Xue ban = J Sichuan U 2005, 36:800-803.
22. Coronella-Wood J.A., Hersh E.M. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003, 52:715-738.
23. Tschernatsch M., Gross O., Kneifel N., Kaps M., Blaes F. SOX-one autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev 2009, 8:549-551.
24. Titulaer M.J., Klooster R., Potman M., Sabater L., Graus F., Hegeman I.M., et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: Frequency and relation with survival. J Clin Oncol 2009, 27:4260-4267.
25. Koopman P. Sex determination: A tale of two sox genes. Trends Genet 2005, 21:367-370.
26. Hammerschmidt W., Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin disease. Trends Mol Med 2004, 10:331-336.
27. Luo Y.L., Ou G.P., Chi P.D., Liang Y.N., Liu Y.H., Huang M.Y. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chin J of Cancer 2009, 28:76-78.
28. Tamori A., Hayashi T., Shinzaki M., Kobayashi S., Iwai S., Enomoto M., et al. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol 2009, 81:1009-1014.
29. Naniche D. Human immunology of measles virus infection. Curr Top Microbiol Immunol 2009, 330:151-171.
30. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(5 Suppl):S45-S55.
31. Croce C.M. Oncogenes and cancer. N Engl J Med 2008, 358:502-511.
32. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High-titer Her-2/neu Protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-3367.
33. Ward R.L., Hawkins N.J., Coomber D., Disis M.L. Antibody immunity to the Her-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999, 60:510-515.
34. Yamamoto A., Shimizu E., Takeuchi E., Houchi H., Doi H., Bando H., et al. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999, 56:129-133.
35. Shi F.D., Zhang J.Y., Liu D., Rearden A., Elliot M., Nachtsheim D., et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005, 63:252-258.
36. Saif M.W., Zalonis A., Syrigos K. The clinical significance of autoantibodies in gastrointestinal malignancies: An overview. Expert Opin Biol Ther 2007, 7:493-507.
37. Yao X., Jiang H., Zhang C., Wang H., Yang L., Yu Y., et al. Dickkopf-one autoantibody is a novel serological biomarker for non-small cell lung cancer. Biomarkers 2009.
38. Tong Y.Q., Liu B., Huang J., Liu Y., Guo F.J., Zhou G.H., et al. BMI-one autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma. Cancer Biol Ther 2008, 7:340-344.
39. Bei R., Budillon A., Reale M.G., Capuano G., Pomponi D., Budillon G., et al. Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res 1999, 59:5471-5474.
40. Ladd J., Lu H., Taylor A.D., Goodell V., Disis M.L., Jiang S. Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf 2009, 70:1-6.
41. Castaneda J.A., Pearce D.A. Identification of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol Dis 2008, 29:92-102.
42. Saffroy R., Lelong J.C., Azoulay D., Salvucci M., Reynes M., Bismuth H., et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999, 79:604-610.
43. Lubin R., Schlichtholz B., Teillaud J.L., Garay E., Bussel A., Wild C.P. p53 antibodies in patients with various types of cancer: Assay, identification, and characterization. Clin Cancer Res 1995, 1:1463-1469.
44. Lubin R., Schlichtholz B., Bengoufa D., Zalcman G., Tredaniel J., Hirsch A., et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 1993, 53:5872-5876.
45. Weller M., Bornemann A., Stander M., Schabet M., Dichgans J., Meyermann R. Humoral immune response to p53 in malignant glioma. J Neurol 1998, 245:169-172.
46. Davidoff A.M., Iglehart J.D., Marks J.R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992, 89:3439-3442.
47. Raedle J., Oremek G., Welker M., Roth W.K., Caspary W.F., Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996, 13:241-246.
48. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353:1224-1235.
49. Chatterjee M., Tainsky M.A. Non-traditional immunogens and their application to immunotherapy. Curr Opin Mol Ther 2008, 10:62-67.
50. Yewdell J.W., Nicchitta C.V. The DRiP hypothesis decennial: Support, controversy, refinement and extension. Trends Immunol 2006, 27:368-373.
51. Toothaker T.B., Rubin M. Paraneoplastic neurological syndromes: A review. Neurologist 2009, 15:21-33.
52. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 2009, 8:410-414.
53. Lloyd K.O., Old L.J. Human monoclonal antibodies to glycolipids and other carbohydrate antigens: Dissection of the humoral immune response in cancer patients. Cancer Res 1989, 49:3445-3451.
54. Almeida L.G., Sakabe N.J., deOliveira A.R., Silva M.C., Mundstein A.S., Cohen T., et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009, 37(Database issue):D816-D819.
55. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (New York, NY1991. Decision;13:1643-7.
56. Costa F.F., Le Blanc K., Brodin B. Concise review: Cancer/testis antigens, stem cells, and cancer. Stem Cells 2007, 25:707-711.
57. Nicholaou T., Ebert L., Davis I.D., Robson N., Klein O., Maraskovsky E., et al. Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell biol 2006, 84:303-317.
58. Gnjatic S., Nishikawa H., Jungbluth A.A., Gure A.O., Ritter G., Jager E., et al. NY-ESO-one: Review of an immunogenic tumor antigen. Adv Cancer Res 2006, 95:1-30.
59. Coulie P.G., Karanikas V., Lurquin C., Colau D., Connerotte T., Hanagiri T., et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002, 188:33-42.
60. Maio M., Coral S., Sigalotti L., Elisei R., Romei C., Rossi G., et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: Expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 2003, 88:748-754.
61. Ralhan R., Nath N., Agarwal S., Mathur M., Wasylyk B., Shukla N.K. Circulating p53 antibodies as early markers of oral cancer: Correlation with p53 alterations. Clin Cancer Res 1998, 4:2147-2152.
62. Lubin R., Zalcman G., Bouchet L., Tredanel J., Legros Y., Cazals D., et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995, 1:701-702.
63. Lu H., Goodell V., Disis M.L. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008, 7:1388-1394.
64. Chapman C., Murray A., Chakrabarti J., Thorpe A., Woolston C., Sahin U., et al. Autoantibodies in breast cancer: Their use as an aid to early diagnosis. Ann Oncol 2007, 18:868-873.
65. Sreekumar A., Laxman B., Rhodes D.R., Bhagavathula S., Harwood J., Giacherio D., et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004, 96:834-843.
66. Nzula S., Going J.J., Stott D.I. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003, 63:3275-3280.
67. Coronella J.A., Spier C., Welch M., Trevor K.T., Stopeck A.T., Villar H., Hersh E.M. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002, 169:1829-1836.
68. Phan T.G., Paus D., Chan T.D., Turner M.L., Nutt S.L., Basten A., Brink R. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 2006, 203:2419-2424.
69. Coronella J.A., Telleman P., Kingsbury G.A., Truong T.D., Hays S., Junghans R.P. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 2001, 61:7889-7899.
70. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9:212.
71. Angelopoulou K., Stratis M., Diamandis E.P. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 1997, 70:46-51.
72. Tangkijvanich P., Janchai A., Charuruks N., Kullavanijaya P., Theamboonlers A., Hirsch P., et al. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma. Asian Pacific J Allerg Immunol 2000, 18:237-243.
73. Tang R., Ko M.C., Wang J.Y., Changchien C.R., Chen H.H., Chen J.S., et al. Humoral response to p53 in human colorectal tumors: A prospective study of 1,two hundred and nine patients. Int J Cancer 2001, 94:859-863.
74. Jager E., Stockert E., Zidianakis Z., Chen Y.T., Karbach J., Jager D., et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-one: Correlation with clinical events. Int J Cancer 1999, 84:506-510.
75. van Rhee F., Szmania S.M., Zhan F., Gupta S.K., Pomtree M., Lin P., et al. NY-ESO-one is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 105:3939-3944.
76. Fossa A., Berner A., Fossa S.D., Hernes E., Gaudernack G., Smeland E.B. NY-ESO-one protein expression and humoral immune responses in prostate cancer. Prostate 2004, 59:8.
77. Akcakanat A., Kanda T., Koyama Y., Watanabe M., Kimura E., Yoshida Y., et al. NY-ESO-one expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004, 54:95-100.
78. DiFronzo L.A., Gupta R.K., Essner R., Foshag L.J., O'Day S.J., Wanek L.A., et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002, 20:3242-3248.
79. von Mensdorff-Pouilly S., Gourevitch M.M., Kenemans P., Verstraeten A.A., Litvinov S.V., van Kamp G.J., et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996, 32A:1325-1331.
80. Orozco J.J., Carter J.J., Koutsky L.A., Galloway D.A. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol 2005, 79:9503-9514.
81. Frazer I.H. Interaction of human papillomaviruses with the host immune system: A well evolved relationship. Virology 2009, 384:410-414.
82. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
83. Slavin S., Morecki S., Weiss L., Or R. Donor lymphocyte infusion: The use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 2002, 11:265-276.
84. Wood W.C., Kornblith P.L., Quindlen E.A., Pollock L.A. Detection of humoral immune response to human brain tumors: Specificity and reliability of microcytotoxicity assay. Cancer 1979, 43:86-90.
85. Brown D.M., Fisher T.L., Wei C., Frelinger J.G., Lord E.M. Tumours can act as adjuvants for humoral immunity. Immunology 2001, 102:486-497.
86. Martin N.H. The immunoglobulins: A review. J Clin Pathol 1969, 22:117-131.
87. Tan P.S., Gavin A.L., Barnes N., Sears D.W., Vremec D., Shortman K., et al. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 2003, 170:2549-2556.
88. Weng W.K., Czerwinski D., Timmerman J., Hsu F.J., Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004, 22:4717-4724.
89. Clémenceau B., Congy-Jolivet N., Gallot G., Vivien R., Gaschet J., Thibault G., Vié H. Antibody-dependent cellular toxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 2006, 107:8.
90. + T cells after Fc gamma RII-mediated uptake. J Exp Med 2006, 203:1629-1635.
91. Nishikawa H., Tanida K., Ikeda H., Sakakura M., Miyahara Y., Aota T., et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci U S A 2001, 98:14571-14576.
92. Dhodapkar K.M., Krasovsky J., Williamson B., Dhodapkar M.V. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002, 195:125-133.
93. Friedrichs B., Siegel S., Kloess M., Barsoum A., Coggin J., Rohrer J., et al. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. J Immunol 2008, 180:6374-6384.
94. Cassard L., Cohen-Solal J.F., Fournier E.M., Camilleri-Broet S., Spatz A., Chouaib S., et al. Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer 2008, 123:2832-2839.
95. Nyhus J.K., Wolford C.C., Friece C.R., Nelson M.B., Sampsel J.W., Barbera-Guillem E. IgG-recognizing shed tumor-associated antigens can promote tumor invasion and metastasis. Cancer Immunol Immunother 2001, 50:361-372.
96. Moons L.M., Kusters J.G., Bultman E., Kuipers E.J., van Dekken H., Tra W.M., et al. Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol 2005, 207:269-276.
97. Fagiolo U., Amadori A., Biselli R., Paganelli R., Nisini R., Cozzi E., et al. Quantitative and qualitative analysis of anti-tetanus toxoid antibody response in the elderly. Humoral immune response enhancement by thymostimulin. Vaccine 1993, 11:1336-1340.
98. Trieb K., Gerth R., Holzer G., Grohs J.G., Berger P., Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 2000, 82:85-87.
99. Fernandez Madrid F. Autoantibodies in breast cancer sera: Candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005, 230:187-198.
100. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., et al. Vaccination with NY-ESO-one protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007, 104:8947-8952.
101. Milne K., Barnes R.O., Girardin A., Mawer M.A., Nesslinger N.J., Ng A., et al. Tumor-infiltrating T cells correlate with NY-ESO-one-specific autoantibodies in ovarian cancer. PLoS ONE 2008, 3:e3409.
102. Tureci O., Sahin U., Schobert I., Koslowski M., Scmitt H., Schild H.J., et al. The SSX-two gene, which is involved in the t(X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996, 20:4766-4772.
103. Chen Y.T., Gure A.O., Tsang S., Stockert E., Jager E., Knuth A., Old L.J. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 1998, 95:6919-6923.
104. Talpaz M., Qiu X., Cheng K., Cortes J.E., Kantarjian H., Kurzrock R. Autoantibodies to Abl and Bcr proteins. Leukemia 2000, 14:1661-1666.
105. Old L.J. Cancer immunology: The search for specificity-G. HA Clowes memorial lecture. Cancer Res 1981, 41:361-375.
106. Wasserman J., Glas U., Blomgren H. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin Exp Immunol 1975, 19:417-422.
107. Al-Shukaili A., Al-Jabri A.A., Al-Moundhri M.S. Prognostic value of auto-antibodies in the serum of Omani patients with gastric cancer. Saudi Med J 2006, 27:1873-1877.
108. Barbouche M.R., Romain S., Avrameas S., Piana L., Martin P.M. Prognostic significance of autoantibodies to laminin in the sera of breast cancer patients: A preliminary report. Eur J Clin Chem Clin Biochem 1994, 32:511-514.
109. Conroy S.E., Faulds G.B., Williams W., Latchman D.S., Isenberg D.A. Detection of autoantibodies to the 90 kDa heat shock protein in systemic lupus erythematosus and other autoimmune diseases. Br J Rheumatol 1994, 33:923-926.
110. Soussi T. p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000, 60:1777-1788.
111. Brankin B., Skaar T.C., Brotzman M., Trock B., Clarke R. Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol Biomarkers Prev 1998, 7:1109-1115.
112. Parmigiani R.B., Bettoni F., Grosso D.M., Lopes A., Cunha I.W., Soares F.A., et al. Antibodies against the cancer-testis antigen CTSP-one are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer 2008, 122:2385-2390.
113. Blaes F., Klotz M., Huwer H., Straub U., Kalweit G., Schimrigk K., Schäfers H.J. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000, 69:254-258.
114. Syrigos K.N., Charalampopoulos A., Konstantoulakis M.M., Karayiannakis A., Tsibloulis V., Peveretos P. Autoantibodies against cardiolipin in the serum of patients with colorectal adenocarcinoma: Their prognostic significance. Eur Surg Res Europaische Chirurgische Forsch 1998, 30:55-60.
115. Yang X.F., Wu C.J., McLaughlin S., Chillemi A., Wang K.S., Canning C., et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 2001, 98:7492-7497.
116. Pallasch C.P., Struss A.K., Munnia A., Konig J., Steudel W.I., Fischer U., Meese E. Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005, 117:456-459.
117. Syrigos K.N., Charalampopoulos A., Pliarchopoulou K., Syrigou E.I., Avuzuklidou M., Manouras A., Leandros M. Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Hybridoma 1999, 18:543-546.
118. Syrigos K.N., Charalambopoulos A., Pliarchopoulou K., Varsamidakis N., Machairas A., Mandrekas D. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res 2000, 20:4351-4353.
119. Hirasawa Y., Kohno N., Yokoyama A., Kondo K., Hiwada K., Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000, 161:589-594.
120. Richards E.R., Devine P.L., Quin R.J., Fontenot J.D., Ward B.G., McGuckin M.A. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998, 46:245-252.
121. Kurtenkov O., Klaamas K., Mensdorff-Pouilly S., Miljukhina L., Shljapnikova L., Chuzmarov V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: Relation to survival. Acta Oncol 2007, 46:316-323.
122. Kocer B., McKolanis J., Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol 2006, 6:4.
123. Vural B., Chen L.C., Saip P., Chen Y.T., Ustuner Z., Gonen M., et al. Frequency of SOX Group. B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 2005, 103:2575-2583.
124. Lakota J., Skultety L., Dubrovcakova M., Altaner C. Presence of serum carbonic anhydrase autoantibodies in patients relapsed after autologous stem cell transplantation indicates an improved prognosis. Neoplasma 2008, 55:488-492.
125. Haidopoulos D., Konstadoulakis M.M., Antonakis P.T., Alexiou D.G., Manouras A.M., Katsaragakis S.M., Androulakis G.F. Circulating anti-CEA antibodies in the sera of patients with breast cancer. Eur J Surg Oncol 2000, 26:742-746.
126. Bachelot T., Ratel D., Menetrier-Caux C., Wion D., Blay J.Y., Berger F. Autoantibodies to endostatin in patients with breast cancer: Correlation to endostatin levels and clinical outcome. Br J Cancer 2006, 94:1066-1070.